AscellaHealth Releases Q1 2024 Specialty & Rare Pipeline Digest™: Captures Data and Progress of Groundbreaking Therapies in 2024
March 28 2024 - 10:00AM
Business Wire
AscellaHealth, a global healthcare and specialty pharmacy
solutions organization, today released its latest Specialty &
Rare Pipeline Digest™, the industry’s most comprehensive
quarterly resource of new, pending and upcoming Specialty and Rare
Disease drug launches, cell and gene therapies (CGT), biosimilars
and generics. Continuing its tradition of providing a quarterly,
complimentary, digital source of industry information to support
the specialty drug market needs of all stakeholders and
decision-makers, AscellaHealth captures essential information and
updates on products that may impact treatment for millions of
individuals worldwide who are affected by complex, chronic
conditions or rare diseases.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240328442451/en/
(Graphic: Business Wire)
“This comprehensive, timely report provides valuable insights
and current data, reflecting the multitude of specialty products
poised for introduction during the first quarter of 2024,” says
Andy Szczotka, PharmD, chief pharmacy officer, AscellaHealth. “We
are impressed with this level of progress and pleased to share this
information in support of the entire specialty pharmaceutical
ecosystem.”
The Specialty & Rare Pipeline Digest™ complements the role
of AscellaHealth as a single-source industry partner, providing
end-to-end, global solutions which result in the streamlined
commercialization of specialty drugs, cost savings for clients and
an optimal treatment journey for patients and family caregivers.
Core Services include:
- Pre-Commercialization & Market Access
- Exclusive Distribution, Wholesale and 3PL Services
- International Specialty Pharmacy Fulfillment
- Comprehensive HUB and Patient Support Services
- Custom Compliance and Persistency Programs
- Streamlined Prior Authorizations
- Technology-based Patient Engagement
- Integrated Copay and Financial Assistance Programs
- Real-time Rx Data and Analytics
- Specialty Pharmacy & Medical Benefit Management
Pointing to the quarterly Specialty & Rare Pipeline Digest™
as the industry’s most comprehensive document detailing the recent
branded specialty drug approvals, upcoming Food & Drug
Administration (FDA) reviews and the CGT and biosimilars pipelines,
Dea Belazi, CEO, AscellaHealth, states, “This educational material
empowers stakeholders with important information that is intended
to enhance treatment access, improve patient care and optimize
clinical outcomes.”
Access the latest Specialty & Rare Pipeline Digest™
here.
About AscellaHealth LLC AscellaHealth, a global
healthcare and specialty pharmacy solutions organization, serving
patients, life sciences manufacturers, payers and providers, offers
a comprehensive portfolio of uniquely tailored, tech-enabled
services supporting complex, chronic conditions or rare diseases
that require specialty medications and/or cell and gene therapies.
A recipient of numerous industry awards for innovation, including
Deloitte Technology Fast 500™ and Inc. 5000, AscellaHealth’s
customized, patient-centric approach is built upon proprietary
technology processes for end-to-end solutions to streamline the
commercialization of specialty medications and proactively address
unmet client needs, optimize clinical health outcomes and improve
the quality of life for this patient population. AscellaHealth
brings a rare and special perspective to all stakeholders. Visit
www.AscellaHealth.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240328442451/en/
Media: Nicole Dufour CPR Communications
ndufour@cpronline.com 201.641.1911 x 54
Marketing: Darcey McDermott, Chief Marketing &
Communications Officer AscellaHealth
darcey.mcdermott@ascellahealth.com 877.389.9040